Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZNGA
ZYNGA INC. CL A COMMON
ZNGA
|
+$391M |
| 2 |
TransUnion
TRU
|
+$345M |
| 3 |
CERN
Cerner Corp
CERN
|
+$309M |
| 4 |
XYZ
Block Inc
XYZ
|
+$266M |
| 5 |
ATVI
Activision Blizzard
ATVI
|
+$261M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$561M |
| 2 |
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
|
+$406M |
| 3 |
RTX Corp
RTX
|
+$227M |
| 4 |
Charter Communications
CHTR
|
+$206M |
| 5 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.5% |
| 2 | Technology | 15.84% |
| 3 | Financials | 13.74% |
| 4 | Industrials | 11.78% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Revolution Medicines
RVMD
$44.9B
| $82.9M | 0.4% |
3,250,000
+500,000
| +18% | +$10.9M |
|
|
CTLT
52
DELISTED
CATALENT, INC.
CTLT
| $79.5M | 0.38% |
716,555
-47,006
| -6% | -$4.91M |
|
53
Sarepta Therapeutics
SRPT
$1.98B
| $77.5M | 0.37% |
991,975
+152,966
| +18% | +$11.7M |
|
|
ZEN
54
DELISTED
ZENDESK INC
ZEN
| $75.8M | 0.37% |
630,000
+200,000
| +47% | +$21.7M |
|
55
PG&E
PCG
$38.8B
| $75.3M | 0.36% |
6,305,142
| – | – |
|
|
AMRS
56
DELISTED
Amyris Inc.
AMRS
| $73.8M | 0.36% |
16,931,427
+6,071,616
| +56% | +$27.2M |
|
57
Inspire Medical Systems
INSP
$1.8B
| $72.8M | 0.35% |
+283,500
| New | +$64.8M |
|
|
CHNG
58
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $71.4M | 0.34% |
3,273,600
| – | – |
|
59
Cytokinetics
CYTK
$10.7B
| $69.3M | 0.33% |
1,882,599
-287,743
| -13% | -$10.2M |
|
60
Bruker
BRKR
$9.07B
| $68.3M | 0.33% |
1,061,800
+316,534
| +42% | +$21.6M |
|
61
United Therapeutics
UTHR
$22B
| $68.1M | 0.33% |
379,696
+58,936
| +18% | +$11.2M |
|
62
Healthcare Realty
HR
$6.65B
| $64.1M | 0.31% |
+2,044,181
| New | +$64.4M |
|
|
ATTO
63
DELISTED
Atento S.A.
ATTO
| $61.7M | 0.3% |
2,230,357
| – | – |
|
|
EXAS
64
DELISTED
Exact Sciences
EXAS
| $56.1M | 0.27% |
802,898
+481,000
| +149% | +$35.2M |
|
65
Jazz Pharmaceuticals
JAZZ
$16.5B
| $51.2M | 0.25% |
329,000
-102,021
| -24% | -$14.8M |
|
|
IMGO
66
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $47.6M | 0.23% |
2,471,313
| – | – |
|
|
OCDX
67
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $45.3M | 0.22% |
+2,426,913
| New | +$43.7M |
|
68
Natera
NTRA
$47.9B
| $44.8M | 0.22% |
1,101,252
-371,463
| -25% | -$22.3M |
|
|
KRTX
69
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $44.4M | 0.21% |
350,000
-200,000
| -36% | -$22.5M |
|
|
DIDI
70
DELISTED
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
| $42.2M | 0.2% |
+16,868,328
| New | +$66.6M |
|
|
BRMK
71
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $42M | 0.2% |
4,850,000
| – | – |
|
72
Repligen
RGEN
$10.2B
| $41.9M | 0.2% |
222,979
+86,734
| +64% | +$16.5M |
|
73
Biogen
BIIB
$32B
| $41.7M | 0.2% |
197,799
+50,090
| +34% | +$10.9M |
|
74
Agios Pharmaceuticals
AGIO
$1.98B
| $38.8M | 0.19% |
1,333,012
+76,434
| +6% | +$2.34M |
|
|
MANT
75
DELISTED
Mantech International Corp
MANT
| $32.3M | 0.16% |
+375,000
| New | +$30M |
|
Similar funds
Thomas Steyer's Q1 2022 Portfolio in Review
As of Q1 2022, Thomas Steyer held 357 positions worth $20.7B, up 3.5% from $20B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Thomas Steyer deployed $853M of net new capital in Q1 2022, opening 50 new positions and adding to 42 existing holdings. Its largest new stake was ZYNGA INC. CL A COMMON: 44,475,000 shares worth $411M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was RTX Corp, an estimated $227M trimmed.
- Thomas Steyer's largest Q1 2022 buy was ZYNGA INC. CL A COMMON: 44,475,000 shares worth $411M.
- Thomas Steyer added most to TransUnion in Q1 2022, an estimated $345M increase.
- Thomas Steyer's biggest Q1 2022 reduction was RTX Corp, cutting an estimated $227M.
- Thomas Steyer fully exited Xilinx Inc in Q1 2022, selling an estimated $561M.
- Thomas Steyer's ten largest holdings make up 38% of its $20.7B portfolio in Q1 2022.
- Thomas Steyer opened 50 new positions and closed 37 in Q1 2022.
- Thomas Steyer's portfolio value rose 3.5% quarter-over-quarter to $20.7B.
Based on Farallon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.